406 related articles for article (PubMed ID: 23273404)
41. A history of early stent thrombosis is associated with prolonged clot lysis time.
Pankiw-Bembenek O; Zalewski J; Goralczyk T; Undas A
Thromb Haemost; 2012 Mar; 107(3):513-20. PubMed ID: 22274545
[TBL] [Abstract][Full Text] [Related]
42. Determinants of hypofibrinolysis in patients with digestive tract cancer.
Gronostaj K; Richter P; Nowak W; Undas A
Prz Gastroenterol; 2016; 11(2):104-10. PubMed ID: 27350837
[TBL] [Abstract][Full Text] [Related]
43. Fibrin clot properties and haemostatic function in men and women with type 1 diabetes.
Tehrani S; Jörneskog G; Ågren A; Lins PE; Wallén H; Antovic A
Thromb Haemost; 2015 Feb; 113(2):312-8. PubMed ID: 25318636
[TBL] [Abstract][Full Text] [Related]
44. Prothrombotic clot properties can predict venous ulcers in patients following deep vein thrombosis: a cohort study.
Polak MW; Siudut J; Plens K; Undas A
J Thromb Thrombolysis; 2019 Nov; 48(4):603-609. PubMed ID: 31432450
[TBL] [Abstract][Full Text] [Related]
45. Altered Fibrin Clot Properties in Patients With Cerebral Venous Sinus Thrombosis: Association With the Risk of Recurrence.
Siudut J; Świat M; Undas A
Stroke; 2015 Sep; 46(9):2665-8. PubMed ID: 26173730
[TBL] [Abstract][Full Text] [Related]
46. Acute CO poisoning is associated with impaired fibrinolysis and increased thrombin generation.
Gawlikowski T; Gomolka E; Piekoszewski W; Jawień W; Undas A
Basic Clin Pharmacol Toxicol; 2013 May; 112(5):352-6. PubMed ID: 23228150
[TBL] [Abstract][Full Text] [Related]
47. Plasma homocysteine affects fibrin clot permeability and resistance to lysis in human subjects.
Undas A; Brozek J; Jankowski M; Siudak Z; Szczeklik A; Jakubowski H
Arterioscler Thromb Vasc Biol; 2006 Jun; 26(6):1397-404. PubMed ID: 16574890
[TBL] [Abstract][Full Text] [Related]
48. Restenosis is associated with prothrombotic plasma fibrin clot characteristics in endovascularly treated patients with critical limb ischemia.
Nowakowski T; Malinowski KP; Niżankowski R; Iwaniec T; Undas A
J Thromb Thrombolysis; 2019 May; 47(4):540-549. PubMed ID: 30762155
[TBL] [Abstract][Full Text] [Related]
49. Altered plasma fibrin clot properties in hypertensive patients with obstructive sleep apnoea are improved by continuous positive airway pressure treatment.
Jóźwik-Plebanek K; Prejbisz A; Wypasek E; Pręgowska-Chwała B; Hanus K; Kaszuba AM; Januszewicz M; Bieleń P; Kabat M; Kruk M; Dobrowolski P; Klisiewicz A; Śliwiński P; Januszewicz A; Undas A
J Hypertens; 2017 May; 35(5):1035-1043. PubMed ID: 28141659
[TBL] [Abstract][Full Text] [Related]
50. Fibrin clot structure in patients with end-stage renal disease.
Sjøland JA; Sidelmann JJ; Brabrand M; Pedersen RS; Pedersen JH; Esbensen K; Standeven KF; Ariëns RA; Gram J
Thromb Haemost; 2007 Aug; 98(2):339-45. PubMed ID: 17721616
[TBL] [Abstract][Full Text] [Related]
51. Altered fibrin clot properties are associated with residual vein obstruction: effects of lipoprotein(a) and apolipoprotein(a) isoform.
Undas A; Cieśla-Dul M; Drążkiewicz T; Sadowski J
Thromb Res; 2012 Sep; 130(3):e184-7. PubMed ID: 22762941
[TBL] [Abstract][Full Text] [Related]
52. Studies of fibrin formation and fibrinolytic function in patients with the antiphospholipid syndrome.
Vikerfors A; Svenungsson E; Ågren A; Mobarrez F; Bremme K; Holmström M; Eelde A; Bruzelius M; Elgue G; Wallén H; Antovic A
Thromb Res; 2014 May; 133(5):936-44. PubMed ID: 24630645
[TBL] [Abstract][Full Text] [Related]
53. Plasma fibrin clot properties and cardiovascular mortality in patients with type 2 diabetes: a long-term follow-up study.
Bryk AH; Konieczyńska M; Polak M; Plicner D; Bochenek M; Undas A
Cardiovasc Diabetol; 2021 Feb; 20(1):47. PubMed ID: 33602240
[TBL] [Abstract][Full Text] [Related]
54. Factor XIII Val34Leu polymorphism as a modulator of fibrin clot permeability and resistance to lysis in patients with severe coronary artery disease.
Stepień E; Plicner D; Kapelak B; Wypasek E; Sadowski J; Undas A
Kardiol Pol; 2009 Aug; 67(8A):947-55. PubMed ID: 19784898
[TBL] [Abstract][Full Text] [Related]
55. High-density cholesterol and apolipoprotein AI as modifiers of plasma fibrin clot properties in apparently healthy individuals.
Ząbczyk M; Hońdo Ł; Krzek M; Undas A
Blood Coagul Fibrinolysis; 2013 Jan; 24(1):50-4. PubMed ID: 23037322
[TBL] [Abstract][Full Text] [Related]
56. Low-grade endotoxemia in acute pulmonary embolism: Links with prothrombotic plasma fibrin clot phenotype.
Ząbczyk M; Kruk A; Natorska J; Undas A
Thromb Res; 2023 Dec; 232():70-76. PubMed ID: 37949000
[TBL] [Abstract][Full Text] [Related]
57. Intensive low-density lipoprotein cholesterol lowering improves fibrin clot properties: Association with lipoproteins and C-reactive protein.
Siudut J; Ząbczyk M; Wołkow P; Polak M; Undas A; Jawień J
Vascul Pharmacol; 2022 Jun; 144():106977. PubMed ID: 35283275
[TBL] [Abstract][Full Text] [Related]
58. Fibrin clot properties in acute ischemic stroke: relation to neurological deficit.
Undas A; Slowik A; Wolkow P; Szczudlik A; Tracz W
Thromb Res; 2010 Apr; 125(4):357-61. PubMed ID: 19942259
[TBL] [Abstract][Full Text] [Related]
59. Differences in the mechanism of blood clot formation and nanostructure in infants and children compared with adults.
Ignjatovic V; Pelkmans L; Kelchtermans H; Al Dieri R; Hemker C; Kremers R; Bloemen S; Karlaftis V; Attard C; de Laat B; Monagle P
Thromb Res; 2015 Dec; 136(6):1303-9. PubMed ID: 26522267
[TBL] [Abstract][Full Text] [Related]
60. Fibrin clot formation and fibrinolysis in patients with a history of coronary stent thrombosis.
Godschalk TC; Konings J; Govers-Riemslag JW; Ten Berg JM; Hackeng CM; Ten Cate H
Thromb Res; 2016 Jul; 143():58-62. PubMed ID: 27191854
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
